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Background: Artemether–lumefantrine (AL) has been used as a first-line treatment for 
uncomplicated Plasmodium falciparum malaria in Ethiopia since 2004. Antimalarial drug 
resistance is one of the major obstacles for malaria control and curtails the lifespan of several 
drugs. Thus, continued monitoring of the efficacy of AL is of great public health importance 
in malaria endemic areas.
Objective: This study aimed to investigate the therapeutic efficacy and safety of AL for the 
treatment of uncomplicated P. falciparum malaria in the Dembia district, northwest Ethiopia.
Methods: A prospective study was conducted from April 2015 to February 2016 at Kola Diba 
Health Center (KHC) in the Dembia district to determine the therapeutic efficacy and safety 
of AL for the treatment of uncomplicated P. falciparum monoinfection. Patients were treated 
with the six-dose regimen of AL over 3 days and followed up for 28 days as per the World 
Health Organization protocol.
Results: Of the total 80 patients enrolled in the AL efficacy study, 75 patients completed the 
28 days follow-up. None of the participants reported major adverse events. No early treatment 
failure or late clinical failure were observed during the study, but there were 6 (8.0%) late para-
sitological failures. The uncorrected per protocol cure rate of AL was 92.0 (95% CI: 85.7–98.3). 
Treatment with AL cleared parasitemia and fever in .95% of the patients by day 3.
Conclusion: This study showed that AL is well tolerated and remains efficacious for treat-
ment of uncomplicated P. falciparum malaria in northwest Ethiopia. However, the observed 
late parasitological failures in this study are of a concern and warrant continued monitoring of 
drug efficacy as per the World Health Organization recommendations.
Keywords: artemether–lumefantrine, uncomplicated Plasmodium falciparum, Ethiopia, malaria, 
antimalarial efficacy
Background
Malaria caused by five species of Plasmodium parasites remains a substantial health bur-
den globally. The World Health Organization estimates ~214 million malaria cases and 
438,000 deaths from this disease in the year 2015. More than 88% of the world malaria 
cases and 90% of malaria-related deaths occur in sub-Saharan African countries.1,2
In Ethiopia, malaria is the leading cause of morbidity and mortality, with .5 million 
cases and 70,000 deaths each year. About 75% of the country is malarious, and 60% 
of its population is at risk of this infection.3,4 Plasmodium falciparum and Plasmodium 
vivax are the predominant malaria parasites in Ethiopia, with the former species being 
accountable for ~65%–75% of reported malaria cases and associated with complicated 
clinical manifestations.3,4
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Antimalarial drug resistance is one of the major obstacles 
for malaria control and curtails the lifespan of several drugs. 
Following a widespread failure of chloroquine (CQ) and 
sulfadoxine–pyrimethamine (SP), most malaria endemic 
countries had shifted their malaria treatment policy to 
artemisinin-based combination therapy (ACT). Ethiopia 
has adopted artemether–lumefantrine (AL), an ACT anti-
malarial, as the first-line drug for the treatment of uncom-
plicated P. falciparum malaria in July 2004.5 A baseline 
study conducted in 2004 to assess the efficacy of AL against 
P. falciparum malaria has shown ~100% cure rate.6 Subse-
quent studies from different parts of the country also reported 
the high efficacy of AL with a treatment failure rate not .5%, 
following the 28-day in vivo test protocol.7–11
However, increased tolerance of the parasites to artemisi-
nin-derived antimalarial drugs has already been reported 
from southeast Asian, the historical epicenter for the start of 
antimalarial drug resistance.12–14 Some studies also reported 
the presence of confirmed resistance in this area.14,15 However, 
there is no such report from sub-Saharan African countries.12 
Nevertheless, the ACT antimalarials such as AL, amodi-
aquine–artesunate, and dihydroartemisinin–piperaquine are 
now being deployed intensively in African countries.16–19 Given 
drug pressure is one of the important drivers for selection of 
drug-resistant Plasmodium parasites, continuous monitoring 
of usage and efficacy of these antimalarials has a vital signifi-
cance for malaria control programs. With this regard, the WHO 
recommends strict monitoring of efficacies of antimalarials 
every 2 years for the early detection of resistance development 
and rapid identification of its new foci. Such data are desirable 
both for immediate containment and prevention of antimalarial 
resistance and for timely updates of treatment policy. To this 
end, our study aims to investigate the therapeutic efficacy and 
safety of AL against uncomplicated P. falciparum malaria in 
Dembia district of North Gondar Zone, northwest Ethiopia.
Methods
Study design, period, and site
A prospective study was conducted from April 2015 to 
February 2016 at Kola Diba Health Center (KHC) of the 
Dembia district of the North Gondar Zone, northwest 
Ethiopia. Dembia is located at 729 km north of the country’s 
capital Addis Ababa, close to Lake Tana (the largest lake in 
Ethiopia). The district covers an area of 1,270 km with the 
altitude ranging between 1,750 and 2,100 m above sea level. 
It has an estimated population of ~271,053.19 The district 
is characterized by high malaria transmission rate (peak 
from October to December) and extensive deployment of 
antimalarials, which might select for drug-resistant parasite 
species. P. falciparum and P. vivax were accountable for 75% 
and 25% of malaria cases in the area, respectively.20
sample size determination
The sample size was determined based on the WHO standard 
protocol for evaluating antimalarial therapeutic efficacy.21,22 
Considering the anticipated population proportion of 
clinical failure of 5%, with 95% confidence interval (CI), 
5% precision, and 10% loss to follow-up, 80 patients were 
enrolled.
Patients, treatment, and follow-up
The study subjects were selected based on the following 
inclusion criteria: age .6 months, confirmed infection with 
P. falciparum, initial density of 1,000–100,000 asexual para-
site/μL, and axillary temperature $37.5°C/history of fever. 
Exclusion criteria were pregnancy or breastfeeding, severe 
co-morbidity, co-infections of P. falciparum with other 
Plasmodium species, severe malnutrition, and danger signs 
such as prostration, coma, multiple convulsions, respiratory 
distress, pulmonary edema, jaundice, hyperparasitemia, and 
severe anemia. P. falciparum-positive cases were treated with 
six oral doses of AL (Novartis, Geneva, Switzerland) scaled 
by age/weight according to the national policy. To facilitate 
the follow-up, patients within 20 km distance from KHC 
were enrolled into the study. All study participants were 
followed on days 1, 2, 3, 7, 14, 21, and 28, and on any other 
day if they felt ill.21,22
Clinical and laboratory procedures
The screening was done by clinicians to identify patients 
meeting the inclusion criteria. Data including age, sex, and 
complete medical history, including prior and concomitant 
medications, were recorded at baseline by health personnel 
in an outpatient setting. Similarly, axillary temperature was 
measured at baseline and on the subsequent visits. Finger-
prick blood sample was collected from each patient. Thick 
and thin blood smears were prepared as outlined in malaria 
microscopy using 10% Giemsa stain (pH 7.2) for 10 min.23 
The blood films were prepared for microscopy before treat-
ment on day 0 and on days 1, 2, 3, 7, 14, 21, and 28.
Parasitemia was estimated by counting the number of 
asexual parasites against a number of leukocytes (200+) 
in the thick blood film, based on a putative mean count of 
8,000 leukocytes per μL. The following formula was used 
to determine parasites, density22:
 Parasitemia/μL 
	 = Number of parasites ×	8000/Number of leukocytes 
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A blood slide was declared negative when the examina-
tion of 100 fields did not show the presence of asexual forms 
of P. falciparum.
Outcomes
The WHO protocol was used to assess the therapeutic effi-
cacy of AL against uncomplicated P. falciparum malaria.22 
According to the definition of WHO, early treatment failure 
(ETF) is the development of danger signs on days 1, 2, or 3 
with insufficient parasitemia clearance on day 3 ($25% of 
count on day 0). Patients with danger signs after day 3 or 
history of fever on any day from day 4 to 28 were grouped 
as late clinical failure (LCF), whereas those with parasitemia 
on any day from day 7 to 28 were classified as late parasito-
logical failure (LPF). If parasitemia was absent on day 28, 
it was considered as adequate clinical and parasitological 
response (ACPR).
The secondary outcomes were fever clearance rate: pro-
portion of patients who have fever cleared at day 1, 2, and 3. 
Parasite clearance rate: proportion of patients with negative 
thick blood film smears on days 1, 2, and 3. Gametocyte 
carriage: proportion of patients with gametocytes during the 
course of the study.
Statistical analysis
Data were entered, cleaned, and analyzed using SPSS 
version 20 statistical package software (SPSS, Inc., Chicago, 
IL, USA). Descriptive statistics such as percentages, mean, 
median, standard deviation, and range was applied as appro-
priate. The efficacy assessment was performed by modified 
intention-to-treat (ITT) and per protocol (PP) analysis. 
The ITT population was used for analysis of variables, pri-
mary and secondary efficacy endpoints. The PP employed 
Kaplan–Meier used for analysis of primary outcomes (ETF, 
LCF, LPF, and ACPR). P-values ,0.05 were considered 
statistically significant.
ethical clearance
Ethical clearance was obtained from the institutional ethical 
review board of the University of Gondar. A written informed 
consent was obtained from all study participants. In the case 
of children under the age of 18 years, consent was obtained 
from a parent or legal guardian.
Results
Characteristics of the study participants
A total of 80 consented patients who fulfilled the inclusion 
criteria were enrolled in the study. Of these, 57 of 80 (71.2%) 
were male and 23 of 80 (28.8%) were female. The median 
age (interquartile range [IQR]) of the patients was 20.0 
(13.0). A little over two-thirds (68.8%) of the study partici-
pants were above the age of 15 years. The mean temperature 
(SD) and parasitemia (geometric mean) of the patients were 
37.86 (0.38) and 8377.8, respectively (Table 1). The mean 
parasite density was higher among the participants below 
the age of 5 years (41.05 parasites/μL) than the remaining 
groups (P=0.03) (data not shown). However, there were no 
significant differences in the baseline mean temperature of 
all age groups (Table 2).
Treatment outcomes
Of the total 80 patients enrolled in the AL efficacy study, 
75 patients completed the 28 days follow-up (Figure 1). 
Five patients (6.3%) were censored, three lost to follow-up, 
one missed the evening dose, and one was infected with 
P. vivax on day 21. None of the study participants reported 
severe adverse effects during the follow-up except that 2 of 
80 (2.5%) participants reported common complaints like 
nausea and coughing. Furthermore, there were no ETFs and 
LCFs, but there were six (8.0%) LPFs.
Table 1 Baseline characteristics of study subjects at Kola Diba 
Health Center, northwest Ethiopia, April 2015–February 2016
Characteristics Frequency (%)
gender
Male 57 (71.2)
Female 23 (28.8)
Age group (years)
0–15 25 (31.2)
.15 55 (68.8)
Age (years)
Mean (sD) 22.36 (11.3)
Median (iQR) 20.0 (±13.0)
Range (min–max) 48 (2–50)
Temperature (°C), day 0
Mean temperature (sD) 37.86 (0.38)
Range (min–max) 37.0–38.6
Parasitemia (μL), day 0
Mean (geometric) parasitemia 8377.78
Parasitemia grade, day 0
Moderate (,10,000/μl) 48 (60.0)
severe ($10,000/μl) 32 (40.0)
Abbreviations: iQR, interquartile range; sD, standard deviation.
Table 2 Baseline characteristics of the study participants at Kola 
Diba Health Center, stratified by age group
Characteristics Age groups (years)
0–15 (95% CI) .15 (95% CI)
Mean T (°C) 37.94 (37.8–38.1) 37.83 (37.7–37.9)
MPD (×1,000) 20.43 (10.8–30.1) 12.28 (7.80–16.76)
Abbreviations: CI, confidence interval; MPD, mean parasite density; T, temperature.
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Of these six patients, 83.3% (5/6) were male, and 16.7% 
(1/6) was under 5 years old. The median age of these patients 
was 15 years (IQR ±10.5), and the range was 2–20. In terms of 
parasitemia grade, 66.7% (4/6) had severe parasitemia at the 
baseline, and the mean (SD) parasitemia was 33,900 (15,863). 
Three of the four patients who showed LPF between days 7 
and 14 had severe parasitemia grade at the baseline. But, all of 
these patients were asymptomatic. The uncorrected cure rate 
for the PP and ITT analyses was 92.0 (95% CI: 85.7–98.3) 
and 86.3 (95% CI: 78.5–93.9), respectively (Table 3).
Secondary treatment outcomes
Treatment with AL displayed a rapid parasite clearance and 
fever resolution rates (Table 4). Of all the study participants, 
67.5%, 85%, and 95% cleared parasitemia on days 1, 2, and 
3, respectively. Fever was noted only in 6.3% and 2.5% on 
days 2 and 3, respectively. All of the patients with fever on 
the above-mentioned days were with high parasitemia grades 
on the day of enrollment. Gametocytes were observed in 
2 of the 80 (2.5%) of the study participants on the day of 
enrollment and in 1 of 80 (1.3%) patients on day 1. Patients 
with gametocytes on day 0 cleared the gametocytes on 
days 2 and 3. No gametocytes were observed after day 3. 
In terms of the age group, all gametocyte cases were noted 
among patients over the age of 16 years.
Discussion
In Ethiopia, AL (a.k.a. Coartem®) has been used as a first-line 
drug for treatment of uncomplicated P. falciparum malaria 
and mixed infection since July 2004. However, data on AL 
efficacy from Ethiopia especially from the northwest part 
are scarce.7,8 The emergence of P. falciparum resistance 
to ACT drugs in southeast Asia threatens the current first-
line treatment for severe malaria.14,15 Development of drug 
resistance is a consequence of intensive use/misuse of anti-
malarials, including poor treatment practices, inadequate 
patient adherence, use of artemisinin-based monotherapies 
or substandard forms of antimalarial drugs, and various 
host–parasite interactions.13,24,25 Thus, it is critical to put a 
stringent antimalarial efficacy monitoring system in place to 
ensure early detection of changes in parasite resistance and 
to inform malaria control policymakers.
Our study showed that AL remains efficacious for the 
treatment of malaria by P. falciparum. The PP cure rate of 
AL (92.0%) observed in this study was in line with 92.5% 
Figure 1 Flowchart depicting follow-up and outcomes of the study participants.
Abbreviations: aCPR, adequate clinical and parasitological response; lPF, late 
parasitological failure; lTF, lost to follow up; PV, Plasmodium vivax.
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Table 3 Treatment outcome of the study subjects after follow-
up for 28 days, Kola Diba Health Center, northwest Ethiopia
Outcomes Value (%)
Censored 5 (6.3)
lost to follow-up 3 (3.8)
Missed evening dose 1 (1.3)
infection with different species 1 (1.3)
Failure
Early treatment failure 0 (0.0)
late clinical failure 0 (0.0)
late parasitological failure 6 (8.0)
aCPR-uncorrected 69 (86.3)
Cure rate – per protocol (95% Ci) 92.0 (85.7–98.3)
Cure rate – intention to treat (95% Ci) 86.3 (78.5–93.9)
Abbreviations: aCPR, adequate clinical and parasitological response; Ci, 
confidence interval.
Table 4 Secondary outcomes of the study participants stratified 
by age
Outcomes Age groups (years) Total
0–15 .15
Fever, n/n (%)
Day 1 10/25 (40) 20/55 (36.4) 30/80 (37.5)
Day 2 1/25 (4.0) 4/55 (7.3) 5/80 (6.3)
Day 3 0/25 (0.0) 2/55 (3.6) 2/80 (2.5)
Parasitemia, n/n (%)
Day 1 9/25 (36.0) 17/55 (30.9) 26/80 (32.5)
Day 2 3/25 (12.0) 9/55 (16.4) 12/80 (15.0)
Day 3 1/25 (4.0) 3/55 (5.5) 4/80 (5.0)
Gametocytes, n/N (%)
Day 0 0/25 (0.0) 2/55 (3.6) 2/80 (2.5)
Day 1 0/25 (0.0) 3/55 (5.5) 3/80 (3.8)
Day 2 0/25 (0.0) 2/55 (3.6) 2/80 (2.5)
Day 3 0/25 (0.0) 1/55 (1.8) 1/80 (1.3)
Day 7 0/22 (0.0) 0/55 (0.0) 0/80 (0.0)
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in northwest Ethiopia,7 93% in Togo,18 and 92.5% in Bastar, 
India.26 This finding was also within a range with 96.3% 
cure rate in Kersa,9 97.6% in Metehara10 and 94.4% in 
southwest Ethiopia.11 The high AL efficacy observed in this 
study could be in part ascribed to the fact that distribution 
of this antimalarial is restricted to the government sectors 
to minimize circulations of substandard counterfeit drugs.27 
Further, continuous follow-up of AL usage by health exten-
sion workers might have also improved patients adherence 
to the treatment regimen.
Delays in parasite clearance time have been used 
as an indicator for suspected artemisinin resistance in 
P. falciparum.14,15 In this study, treatment with AL displayed 
rapid parasite and fever clearance rates. All of the patients but 
two were cleared of the fever on day 3. Similarly, ~95% and 
98% of the patients had cleared parasitemia and gametocytes 
on day 3 of treatment, respectively, indicating that AL was 
effective in reduction of the parasite biomass. This finding 
was consistent with therapeutic efficacy values reported by a 
number of previous studies.7,28–30
In terms of tolerability, AL was well tolerated by all study 
participants including the children who were treated by this 
drug. This was consistent with the previous reports.7,17 No 
adverse events were noted in children as well as adolescents 
who took part in this study, but two adults reported the 
well-characterized AL side effects such as nausea and 
coughing.
Given that most of the patients with a delayed parasites 
clearance can still be cured with AL, the treatment failure 
observed in this study might not necessarily mean an emer-
gence of AL-resistant strains. This is because a number of 
factors like host immunity, re-infection, low drug level in 
blood, and recrudescence cases could influence the outcomes 
of a therapeutic efficacy test.31–33 Thus, we recommend fur-
ther investigations with definitive confirmatory tests for AL 
resistance such as in vitro drug susceptibility tests, molecu-
lar markers for drug resistance or to rule out recrudescent/
reinfection cases, and pharmacokinetics.
Nevertheless, the re-emergence of parasitemia as early as 
day 7 after the start of treatment and a relatively high propor-
tion of patients (5%) with parasitemia on day 3 observed in 
this study might have potential clinical implications.
Conclusion
The results of this study demonstrate that AL is well toler-
ated and remains efficacious for treatments of uncomplicated 
P. falciparum malaria in northwest Ethiopia. However, the 
delayed parasitological failures observed in this study suggest 
the need for continued monitoring of drug efficacy as per the 
WHO recommendations.
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